



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C07D 471/00</p>	<p>A2</p>	<p>(11) International Publication Number: WO 00/08020</p> <p>(43) International Publication Date: 17 February 2000 (17.02.00)</p>
<p>(21) International Application Number: PCT/EP99/05584</p> <p>(22) International Filing Date: 3 August 1999[*] (03.08.99)</p> <p>(30) Priority Data: 9817028.5 5 August 1998 (05.08.98) GB</p> <p>(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM P.L.C. [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): COULTON, Steven [GB/GB]; (GB). NOVELLI, Riccardo [IT/GB]; (GB). PORTER, Roderick, Alan [GB/GB]; (GB). THOMPSON, Mervyn [GB/GB]; (GB). WARD, Robert, William [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).</p> <p>(74) Agent: WEST, Vivien; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).</p>		
<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>		
<p>(54) Title: NOVEL COMPOUNDS</p> <div style="text-align: center; margin: 20px 0;"> <p style="text-align: right;">(I)</p> </div>		
<p>(57) Abstract</p> <p>Compounds of formula (I) or salt thereof or solvate thereof, in which: m is 1 or 2; n is 1 or 2; X is CH or N; Y is selected from hydrogen, halogen, cyano, CF₃, alkyl or alkoxy; R¹, which may be at any position within the saturated ring system, is hydrogen or up to two substituents which may be the same or different and each of which is selected from fluoro and C₁₋₆ alkyl; R² is hydrogen or up to four substituents selected from halogen, NO₂, CN, N₃, CF₃O-, CF₃S-, CF₃CO-, C₁₋₆alkenyl, C₁₋₆alkynyl, C₁₋₆perfluoroalkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₄alkyl-, C₁₋₆alkylO-, C₁₋₆alkylCO-, C₃₋₆cycloalkylO-, C₃₋₆cycloalkylCO-, C₃₋₆cycloalkyl-C₁₋₄alkylO-, C₃₋₆cycloalkyl-C₁₋₄alkylCO-, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C₁₋₄alkyl-, C₁₋₆alkylS-, C₁₋₆alkylISO₂-, (C₁₋₄alkyl)₂NHSO₂-, (C₁₋₄alkyl)NHSO₂-, (C₁₋₄alkyl)₂NCO-, oxazolyl, (C₁₋₄alkyl)NHCO-, CONH₂, or R⁴CONH- or -NR⁴R⁵, wherein R⁴ is hydrogen or C₁₋₄ alkyl; and R⁵ is hydrogen, C₁₋₆alkyl, formyl, -CO₂C₁₋₄alkyl or -CO₂C₁₋₄alkyl; or two R⁵ groups are linked together form a carbocyclic or heterocyclic ring that is saturated or unsaturated and unsubstituted or substituted by -OH or -O- are indicated to be useful in the treatment and prophylaxis of epilepsy, migraine, and other disorders.</p>		

00752354-0219002